Rapport Therapeutics, Inc. (RAPP) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $48.00K; Additional Paid in Capital, Common StockUSD $735.85M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.27M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $48.00K; Additional Paid in Capital, Common StockUSD $727.05M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-505.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $48.00K; Additional Paid in Capital, Common StockUSD $719.29M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $546.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $48.00K; Additional Paid in Capital, Common StockUSD $712.89M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $145.00K.
Rapport Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $48.00K | $735.85M | $-1.27M | $-311.70M | $422.93M | 3 month · $7.20M |
| 2026-03-31 | $0.00 | $48.00K | $727.05M | $-505.00K | $-255.09M | $471.51M | 3 month · $6.96M |
| 2025-12-31 | $0.00 | $48.00K | $719.29M | $546.00K | $-235.23M | $484.65M | 12 month · $18.86M |
| 2025-09-30 | $0.00 | $48.00K | $712.89M | $145.00K | $-201.47M | $511.62M | 3 month · $4.74M |
| 2025-06-30 | $0.00 | $37.00K | $438.09M | $-76.00K | $-174.54M | $263.51M | 3 month · $4.39M |
| 2025-03-31 | (m) | $37.00K | $433.70M | $-95.00K | $-147.81M | $285.84M | 3 month · $4.04M |
| 2024-12-31 | $0.00 | $37.00K | $429.66M | $-522.00K | $-123.75M | $305.43M | 12 month · $10.23M |
| 2024-09-30 | (m) | $36.00K | $426.44M | $400.00K | $-103.77M | $323.11M | 3 month · $3.18M |
| 2024-06-30 | $0.00 | $36.00K | $423.26M | $-183.00K | $-86.23M | $336.89M | 3 month · $2.35M |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | $-39.63M | 3 month · $1.49M |
| 2023-12-31 | $0.00 | $4.00K | $19.80M | $4.00K | $-45.44M | $-25.63M | 12 month · $3.52M |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $-13.12M | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $-9.43M | 3 month · $945.00K |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $-4.00M | 3 month · $723.00K |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $-10.06M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |